PF-06426779 is a potent and selective inhibitor of interleukin?1 receptor associated kinase 4 (IRAK4), with an IC50 of 0.3 nM[1].
PF-06426779 inhibits IRAK4, with an IC50 of 12.7 nM in the peripheral blood mononuclear cells (PBMCs) assay[1].
[1]. Lee KL, et, al. Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design. J Med Chem. 2017 Jul 13; 60(13): 5521-5542.